EP4022072A4 - Compositions et méthodes pour le traitement d'infections virales - Google Patents

Compositions et méthodes pour le traitement d'infections virales Download PDF

Info

Publication number
EP4022072A4
EP4022072A4 EP20858496.1A EP20858496A EP4022072A4 EP 4022072 A4 EP4022072 A4 EP 4022072A4 EP 20858496 A EP20858496 A EP 20858496A EP 4022072 A4 EP4022072 A4 EP 4022072A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
viral infections
treating viral
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20858496.1A
Other languages
German (de)
English (en)
Other versions
EP4022072A1 (fr
Inventor
Serhat GUMRUKCU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Tech Bio LLC
Original Assignee
G Tech Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio LLC filed Critical G Tech Bio LLC
Publication of EP4022072A1 publication Critical patent/EP4022072A1/fr
Publication of EP4022072A4 publication Critical patent/EP4022072A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20858496.1A 2019-08-29 2020-08-28 Compositions et méthodes pour le traitement d'infections virales Pending EP4022072A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893460P 2019-08-29 2019-08-29
US202062968387P 2020-01-31 2020-01-31
US202062976491P 2020-02-14 2020-02-14
US202062985597P 2020-03-05 2020-03-05
PCT/US2020/048370 WO2021041787A1 (fr) 2019-08-29 2020-08-28 Compositions et méthodes pour le traitement d'infections virales

Publications (2)

Publication Number Publication Date
EP4022072A1 EP4022072A1 (fr) 2022-07-06
EP4022072A4 true EP4022072A4 (fr) 2023-09-06

Family

ID=74686046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20858496.1A Pending EP4022072A4 (fr) 2019-08-29 2020-08-28 Compositions et méthodes pour le traitement d'infections virales

Country Status (11)

Country Link
EP (1) EP4022072A4 (fr)
JP (1) JP2022546402A (fr)
KR (1) KR20220095183A (fr)
CN (1) CN114761566A (fr)
AU (1) AU2020335886A1 (fr)
BR (1) BR112022003814A2 (fr)
CA (1) CA3149041A1 (fr)
IL (1) IL290826A (fr)
MX (1) MX2022002211A (fr)
WO (1) WO2021041787A1 (fr)
ZA (1) ZA202202370B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231503A2 (fr) * 2020-05-11 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés pour améliorer l'expression génique
US20220282279A1 (en) * 2021-03-06 2022-09-08 Serhat Gumrukcu Compositions and methods for treating and preventing coronavirus infections
JP2025516651A (ja) * 2022-05-13 2025-05-30 サンテック メディカル，インコーポレイティド 感染性疾患を治療するための方法
CN115869394A (zh) * 2022-07-21 2023-03-31 中国食品药品检定研究院 核酸佐剂、含有所述核酸佐剂的疫苗及应用
CN115856299A (zh) * 2022-10-26 2023-03-28 中国科学院海洋研究所 Pck-1在作为海洋生物细菌病原感染的血清分子标志物的应用
CN119405785A (zh) * 2025-01-07 2025-02-11 首都医科大学附属北京儿童医院 Cxcl11作为抗病毒药物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
WO2012170431A2 (fr) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Systèmes perfectionnés de commutation génique
WO2015193484A1 (fr) * 2014-06-20 2015-12-23 Drexel University Antigène e de virus adn de l'hépatite marqué et son utilisation lors d'un criblage de substances antivirales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTZER U ET AL: "INTERFERON GENE TRANSFER BY A HEPATITIS B VIRUS VECTOR EFFICIENTLY SUPPRESSES WILD-TYPE VIRUS INFECTION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 96, no. 19, 14 September 1999 (1999-09-14), pages 10818 - 10823, XP002129421, ISSN: 0027-8424, DOI: 10.1073/PNAS.96.19.10818 *

Also Published As

Publication number Publication date
AU2020335886A1 (en) 2022-03-17
JP2022546402A (ja) 2022-11-04
CA3149041A1 (fr) 2021-03-04
MX2022002211A (es) 2022-05-24
IL290826A (en) 2022-04-01
EP4022072A1 (fr) 2022-07-06
BR112022003814A2 (pt) 2022-05-24
CN114761566A (zh) 2022-07-15
KR20220095183A (ko) 2022-07-06
WO2021041787A1 (fr) 2021-03-04
ZA202202370B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
AU2020342649B2 (en) Compositions and methods for the treatment of viral infections
IL281277A (en) Preparations and methods for treating viral infections
EP4022072A4 (fr) Compositions et méthodes pour le traitement d'infections virales
EP3931336A4 (fr) Compositions et procédés de traitement de laminopathies
EP4213820A4 (fr) Méthodes et compositions pour traiter des infections virales
EP3468593A4 (fr) Compositions et procédés pour prévenir et traiter l'infection par le virus zika
EP4243809A4 (fr) Composés et méthodes de traitement d'infections virales
EP3893785A4 (fr) Compositions et procédés de traitement des plaies
EP3870210A4 (fr) Compositions et procédés de traitement ou de prévention de la fibrose
EP4281096A4 (fr) Procédés et compositions pour traiter des infections
EP3793539A4 (fr) Composés pour le traitement d'une infection par le virus de la dengue et d'autres infections
EP3990472A4 (fr) Compositions et méthodes pour traiter des infections fongiques
EP4367086A4 (fr) Compositions et méthodes de traitement et de prévention d'infections virales
GB201907493D0 (en) Agents and methods for treating viral infections
HK40076807A (en) Compositions and methods for treating viral infections
AU2018904123A0 (en) Compositions and methods for treating viral infections
HK40101021A (en) Methods and compositions for treating viral infections
HK40094722A (en) Compositions and methods for treating viral infections
HK40079133A (en) Compositions and methods for the treatment of viral infections
HK40108955A (en) Compositions and methods for treating and preventing viral infections
HK40052593A (en) Compositions and methods for the treatment of viral infections
HK40071714A (en) Compositions and synergistic methods for treating infections
IL309452A (en) Preparations for the treatment of viral infections and methods thereof
HK40071272A (en) Compositions and methods for treating hepatitis b
EP4167989A4 (fr) Composition pour le traitement d'infections virales

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076807

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

A4 Supplementary search report drawn up and despatched

Effective date: 20230807

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/01 20060101ALI20230801BHEP

Ipc: C12N 15/86 20060101AFI20230801BHEP